Prestige Consumer Healthcare Reaffirms FY25 Outlook For Sales Of $1.125B - $1.14B (Est $1.129B), Adjusted EPS Of $4.40 - $4.46 (Est $4.40)
Portfolio Pulse from Benzinga Newsdesk
Prestige Consumer Healthcare reaffirms its FY25 outlook, projecting sales between $1.125 billion and $1.14 billion, and adjusted EPS between $4.40 and $4.46. These projections align closely with market estimates.
August 08, 2024 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prestige Consumer Healthcare reaffirms its FY25 outlook, projecting sales between $1.125 billion and $1.14 billion, and adjusted EPS between $4.40 and $4.46. These projections align closely with market estimates.
The reaffirmation of the FY25 outlook by Prestige Consumer Healthcare provides a positive signal to investors, as the projections align closely with market estimates. This alignment suggests stability and reliability in the company's financial performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100